Valneva Austria Gmbh

This observational study will follow 5,000 people who received the VLA1553 chikungunya vaccine as part of a pilot vaccination program. Researchers will monitor for specific safety concerns like chikungunya-like reactions, heart problems, and arthritis over 60 days. The goal is to…

This study will track 1200 people in Brazil who received the VLA1553 chikungunya vaccine as part of a pilot program. Researchers will compare how many vaccinated and unvaccinated people get chikungunya to see if the vaccine works in everyday life. The goal is to understand the va…

This Phase 3 trial follows adults who previously received the VLA1553 chikungunya vaccine to see how long their antibodies last and to monitor long-term safety. About 363 participants are being tracked for up to several years. The goal is to determine if a single shot can provide…

This study was designed to test a vaccine called VLA1553 to protect healthy children aged 1 to 11 years from chikungunya, a virus spread by mosquitoes. The plan was to give the vaccine or a comparison shot to over 3,000 children and check for immune responses and safety. However,…

This study follows 200 pregnant women in Brazil who received the chikungunya vaccine (VLA1553) during pregnancy or shortly before. Researchers will track pregnancy and infant health up to 12 weeks after birth, comparing them to a similar group of women who got routine vaccines. T…

This study will test over 5,300 people in about 10 Brazilian municipalities for antibodies to the chikungunya virus before a pilot vaccination campaign with the VLA1553 vaccine. The goal is to see how many people have already been exposed to the virus and how that might affect va…